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ABSTRACT 
Chronic allograft nephropathy (CAN) is a major indication for initiation of sirolimus 
(SRL) in renal transplantation (TX) to prevent deterioration of renal function. We 
evaluated whether the CAN score at time of sirolimus rescue (SRL-R) predicts renal 
allograft function. CAN score is the sum of the following 4 categories: glomerulopathy (cg, 
0-3), interstitial fibrosis (ci, 0-3), tubular atrophy (ct, 0-3), and vasculopathy (cv, 0-3). 
This is a retrospective cohort study of renal transplant recipients from July 2001 to March 
2004. Immunosuppression consisted of preconditioning with rabbit anti-thymocyte globu-
lin or alemtuzumab and maintenance with tacrolimus (TAC) monotherapy with spaced 
weaning, if applicable, SRL-R was achieved by conversion from TAC, or by addition to 
reduced doses of TAC. Ninety patients received SRL. Thirty-three of these patients met 
the inclusion criteria of the following: (1) receipt of SRL for >6 months, and (2) follow-up 
of:=::6 months. There were 16 patients in the low-CAN (0-4) group and 17 patients in the 
high-CAN (>4) group. Cockcroft-Gault (C-G) glomerular filtration rate (GFR) was! 
calculated at SRL-R and at 1, 3, 6, and 12 months. The LlGFR was significantly better in 
the low-CAN group at 1, 3, and 6 months. A trend toward an improved LlGFR was present 
at 12 months in the low-CAN group (P = .16). CAN scoring at the time of SRL-R predicts 
recovery of renal allograft function (as measured using LlGFR), and should be used in 
preference to biochemical markers (Cr and C-G GFR), which may not be reliable 
predictors. 
THE MOST common causes of late renal allograft loss 
are chronic renal allograft dysfunction (CRAD) and 
death with a functioning graft (DWFG).l A major cause of 
CRAD is chronic allograft nephropathy (CAN). 
CAN is progressive long-term condition characterized by 
interstitial fibrosis, tubular atrophy, vascular occlusive 
changes, and glomerulosclerosis.v There are 2 distinct 
phases of injury: an initial phase and a later phase. Each 
phase represents cumulative and progressive damage from 
both immunologic and nonimmunologic etiologies.4 
Chronic changes are scored for the glomerulopathy (cg), 
interstitial fibrosis (ct), tubular atrophy (ct), and vasculopa-
thy (cv). It is possible to apply relative weightings and 
calculate overall severity scores (such as the CAN score) 
using this coding system.2 In the Banff classification, the 
following histological patterns have been defined: CAN (a): 
interstitial fibrosis, tubular atrophy and/or loss, glomeru-
!opathy, and mesangial matrix increase (grades 1-3a); CAN 
(b): interstitial fibrosis, tubular atrophy and/or loss, to-
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gether with typical vascular lesions and mononuclear infil-
trates (grades 1-3b); and calcineurin inhibitor (CNI) neph-
rotoxicity: hyaline changes particularly in the afferent 
arterioles of the glomerulus and vacuolation of tubular 
epithelial cells.3 
The CNls Tacrolimus (TAC) and cyclosporine (CsA) 
have been mainstays of chronic immunosuppression be-
cause of a decreased incidence of acute rejection and also 
improved allograft and patient survival rates in recent 
decades. 1 eNI drugs cause progressive renal injury related 
to direct nephrotoxicity; the continued use of CNI agents 
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contributes to the development of CAN.5 There is a high 
incidence of CAN in patients using Tacrolimus as main-
tenance immunosuppression - 67% at 2 years after 
renal transplantation.6 Thus, although there has been a 
dramatic increase in kidney graft survival with TAC, 
CNI-related nephrotoxicity may compromise long-term 
outcomes.7 The reduction or withdrawal of CNI in combi-
nation with alternative immunosuppressive regimens such 
as sirolimus (SRL) has become a popular practice in renal 
transplantation. 
SRL is a macrocyclic lactone antibiotic produced by 
Streptomyces hygroscopicus. It inhibits the mammalian tar-
get of rapamycin (mTOR), a kinase in costimulatory and 
cytokine-driven pathways of T-cell regulation.8 - lU SRL 
lacks the acute and chronic nephrotoxic profile of the CNls. 
Because it inhibits growth-factor-induced proliferation of 
fibroblasts, endothelial cells, hepatocytes, and smooth mus-
cle cells, it offers an important alternative to CNI drugs to 
prevent CAN.l! 
The reduction or withdrawal of CNI in combination with 
sirolimus rescue (SRL-R) has been a growing topic of 
interest. Improvements in renal function have been shown 
in patients with CAN (b) and CNI nephrotoxicity with 
SRL-R therapy. Allograft function was less likely to im-
prove for patients with CAN (a) or serum creatinine level 
>400 j.LmollL. 12 
At the American Transplant Congress (ATC) in 2003, we 
presented the University of Pittsburgh Medical Center's 
(UPMC) experience with SRL-R in kidney and kidney! 
pancreas transplant recipients. 13 Other clinical studies have 
tried to identify independent factors that predict successful 
conversion from T AC to SRL in patients with CAN. 14.15 
Among the factors that predict success in conversion 
from T AC to SRL in CAN are serum creatinine level at the 
time of conversion, 14 and degree of CAN, as assessed using 
the CAN score at the time of SRL conversion. 
No clinical studies have evaluated the allograft outcomes 
in antibody preconditioned patients with regard to SRL-R 
from T AC-based immunosuppression. The purpose of this 
current retrospective study was to determine if the CAN 
score at the time of SRL-R predicts subsequent renal 
allograft function. Changes in calculated glomerular filtra-
tion rate (GFR) were evaluated in patients who had received 
antibody preconditioning with rabbit anti-thymocyte globu-
lin or alemtuzumab to see if CAN score2•3 at SRL-R was a 
significant predictor of subsequent renal allograft function. 
PATIENTS AND METHODS 
This retrospective cohort study used the in-house database, Elec-
tronic Data Interface for Transplantation (EDIT), at the Thomas 
E. Starz! Transplantation Institute at the University of Pittsburgh 
Medical Center. Evaluation of all the renal allograft recipients 
from July 1, 2001 to March 31, 2004 yielded 190 patients diagnosed 
with CAN based on renal biopsy specimen. Of these 190 patients 
with CAN, 90 had received SRL-R from TAC From this patient 
population, 33 satisfied the inclusion criteria of the following: 
(1) no extra-renal transplant, (2) receipt of SRL for at least 6 
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months, and (3) follow-up maintenance of at least 6 months. 
Patients satisfying all inclusion criteria were divided into 2 groups 
based on the biopsy-reported CAN scoring done by a blinded 
pathologist using the 1997 Banff classification system. CAN score 
was calculated as the sum of the following 4 categories: glomeru-
lopathy (eg. 0-3), interstitial fibrosis (ci, 0-3), tubular atrophy (ct, 
0-3), and vasculopathy (cv, 0-3). Of these 33 patients, 16 were in the 
low-CAN score group with a score ,s4, and 17 were in the high-CAN 
score group with a score >4. Review was made of the clinical 
course, including laboratory values, dosage and trough levels of 
immunosuppressive agents, and steroid and antibody treatment of 
rejection episodes. Data collection was approved by the Institu-
tional Review Board (IRB) of the UPMC 
Immunosuppressive preconditioning had been achieved with 
either Thymoglobulin 5 mg/kg (Sangstat, Fremont, Calif, United 
States (n = 30) or Campath-l H 30 mg (Berlex, Montvale, NJ, 
United States) (n = 3) preoperatively followed by TAC mono-
therapy, with target trough levels of around 10 ng/mL. 16- IB The 
IRB of the University of Pittsburgh judged the above immunosup-
pressive regimen to be within the boundaries of historically based 
standard treatment, not needing formal IRB approval. The Pres-
byterian University Hospital Innovative Practices Committee and 
the Pharmacy and Therapeutics Committee both approved the 
protocol. 
After biopsy-reported CAN scoring, SRL conversion was accom-
plished either by converting (n = 19) from TAC to SRL or by an 
addition (n = 14) of SRL to tapered doses of TAC Eight patients 
in the low-CAN score group had TAC abruptly changed to SRL, 
whereas the remaining 8 patients in the low-CAN scot,e group had 
SRL added to tapered doses of TAC; the other p~ients in each 
category belonged to the high CAN score group. SRL levels were 
maintained at a trough serum level of 5-10 ng/mL either as 
monotherapy or when used with TAC TAC levels were maintained 
at a trough level between 5 and 10 ng/mL when used with SRL. 
Spaced weaning was not carried out for patients on SRL mono-
therapy. Patients with acute rejection based on biopsy specimen 
were treated with corticosteroids and mycophenolate mofetil 
(MMF) as indicated (low-CAN, n = 3; high-CAN, n = 4). 
Serum creatinine level was determined for each patient at the 
time of SRL-R. Cockcroft-Gault glomerular filtration rate (GFR) 
was calculated for each patient at the time of SRL-R and at 1,3, 6, 
and 12 months after SRL-R. The low-CAN and high-CAN groups 
were compared for significant differences in GFR changes with 
Mann-Whitney U tests using SPSS 12.0 software (Chicago, Ill, 
United States), defining statistical significance as P < .05. The 
dynamics of change in the GFR in the low-CAN score and 
high-CAN score groups were evaluated using the Wilcoxon signed 
rank test using SPSS 12.0 software, defining statistical significance 
as P < .05. 
RESULTS 
The characteristics of the study population (n = 33) at 
the time before SRL-R are shown in Table 1. The median 
age in the low-CAN and high-CAN groups was 50.5 years 
and 50.0 years, respectively. The low-CAN group was 
56% male and the high-CAN group was 59% male with no 
age or gender differences between CAN groups. The me-
dian GFR for the low-CAN and high-CAN groups were 
33.0 mLimin and 33.3 mL/min, respectively (P = .51). The 
time from transplantation to the initiation of SRL-R and 
the serum creatinine values at the time of SRL-R were not 
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Table 1. Patient Information Before Initiation of SRL-R 
Low-CAN Group High-CAN Group 
(n = 16) (n = 17) p 
CAN score Median, 3.5 Median, 6.0 
Age (y) 50.5 50.0 .66 
Male:female ratio 9:7 10:7 
Time from transplantation 208 372 .12 
to SRL-R (d) 
Cockcroft-Gault GFR 33.0 33.3 .51 
(mUmin) 
SCr at SRL-R (mg/dL) 2.9 2.5 .36 
Abbreviation: SCr, serum creatinine. 
Note: All values are expressed as median. 
statistically significant between the groups (P = .12 andP = 
.36, respectively). 
The changes in GFR after SRL-R for patients in the 
low-CAN and high-CAN groups are shown in Table 2. For 
patients in the low-CAN group, the average GFR increased 
significantly from baseline at 1, 3, and 6 months after 
SRL-R (P = .006, P = .002, and P = .004, respectively) 
(Wilcoxon signed rank test). The net change in GFR in this 
group was +2.8 mUmin at 12 months; however, this 
positive change was not statistically significant (P = .21). In 
the high-CAN group, there was no significant change in 
GFR at 1, 3, 6, or 12 months from initiation of SRL-R (P = 
.78, P = .49, P = .6, and P = .61, respectively) (Wilcoxon 
signed rank test). 
At the time of SRL-R, there was no difference in GFR 
values between the groups. However, statistically significant 
changes in GFR dynamics did occur between the 2 patient 
groups at 1, 3, and 6 months (P = .008, P = .001, and P = 
.004, respectively) (Mann-Whitney U test). At 12 months, 
the change in GFR was not significantly better in the 
low-CAN score group (P = .16). 
There was 1 patient death each in the low-CAN group 
and the high-CAN group during the I-year follow-up period 
(Table 2). The patient in the low-CAN group died of 
cardiovascular causes with a failing allograft during the 
eighth month following SRL-R. The patient in the high-
CAN group suffered from bipolar disorder and died during 
the 12th month after SRL-R with a functioning allograft. 
Table 2. Effect of SRL-R on Change (4) in GFR in Patients in 
the Low·CAN and High-CAN Groups (Mann·Whitney U Test) 
Low-CAN Group High-CAN Group P 
Cockcroft-Gault GFR 33.0 33.3 .51 
at SRL-R (mUmin) 
IlGFR 1 mo after +11.6 +2.05 .008 
SRL-R (mUmin) 
t.GFR 3 mo after +9.1 -1.4 .001 
SRL-R (mUmin) 
t.GFR 6 mo after +10.2 -0.05 .004 
SRL-R (mUmin) 
IlGFR 12 ma after +2.8 (n=15) -2.75 (n=16) .16 
SRL-R (mUm in) 
Note: All values are expressed as median. 
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Table 3. Patient and Graft Survival Rates and Serum 
Creatinine Levels 1 Year After SRL-R 
Patient survival 
Graft survival 
Death-censored graft survival 
Median SCr (mg/dL) 








Patient survival, graft survival, and serum creatinine level 
year after SRL-R are shown in Table 3, and are not 
significantly different. One graft was lost in the low-CAN 
group in a 75-year-old woman after she developed pulmo-
nary aspergillosis in the ninth month following SRL-R. 
DISCUSSION 
CAN is a major determinant of CRAD leading to worsen-
ing allograft function and allograft loss after renal transplan-
tation. Traditional CNI-based therapies are being reevalu-
ated because they cause direct nephrotoxicity and worsen 
CAN. The mammalian target of rapamycin (mTOR) inhib-
itor SRL has been recently investigated as a subsequent 
substitution therapy for CNI therapy. Because of its lack of 
direct nephrotoxicity, low side effect profile, antitumor 
activity, and effectiveness.8 SRL-R is an intensely studied 
area in renal transplantation, using the initial,benefits of 
TAC while reducing long-term exposure using SRL. 
Previous comparisons of renal transplant recipients with 
CAN (n = 51) receiving SRL·R with a historical control 
group (n = 292) receiving SRL-R did not show any 
differences in patient survival or allograft survival during a 
period of 5 years of follow-up (unpublished data from the 
University of Pittsburgh). This result suggests that patients 
receiving SRL-R had no benefit of therapy, but raised the 
possibility that many of these patients had undergone 
SRL·R when CAN was too advanced. The current study 
suggests that a cohort of patients with a CAN score ::0;;4 will 
benefit from SRL-R as measured by significantly improved 
GFR measurements for up to 6 months of follow-up after 
SRL-R. 
This study shows that CAN scoring at the time of SRL-R 
can predict recovery of renal allograft function as measured 
using changes in GFR. Statistical significance for improved 
GFR was reached at 1, 3, and 6 months after SRL-R in the 
low-CAN group compared with the high-CAN group. For 
patients within the low-CAN group, the mean GFR in-
creased significantly at 1, 3, and 6 months after SRL-R; 
GFR improvement did not reach statistical significance 
after 1 year of follow-up (P = .21), although a net change of 
+2.8 mL/min was seen. Within the high-CAN group, im-
provement in GFR did not occur. In spite of these differ-
ences, there were no differences in patient or graft survival 
or quality of kidney function. 
Factors predicting the success of SRL-R are still under 
investigation for different patient groups. Previous studies 
have shown that serum creatinine level <2.8 mg/dL, degree 
of CAN, and proteinuria <800 mg/d can predict renal 
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allograft function after SRL_R. 14,IS,I'l In the report by 
Diekmann et a1/5 although proteinuria was the only signif-
icant independent factor, responders had a significantly 
lower grade of CAN and significantly lower grade of 
vascular fibrous intimal thickening than nonresponders, 
This analysis specifically demonstrates that patients with 
a CAN score ::;4 can benefit from SRL-R. In this study, 
patients in the low-CAN group had a median serum creat-
inine level of 2.9 mg/dL, higher than the significant level 
shown in the study by Egidi et a1. 14 Patients in the 
high-CAN group had a median serum creatinine level of 
2.5 mg/dL. Differences were not significant between the 
groups (P = .36). Serum creatinine level may not be a 
reliable predictor of recovery of renal allograft function in 
these patients. 
Proteinuria was not systemically assessed at the time of 
SRL-R in the patient groups in this study. This information 
could have provided additional insight about the value of 
proteinuria in predicting SRL-R success, and is a limitation 
of this study. 
Sankaranarayanan et al19 showed that the Chronic Allo-
graft Damage Index (CADI) score at the time of conversion 
from CNI to SRL was a reliable predictor of renal outcome. 
The CADI consists of the 6 histological changes character-
istic of chronic rejection, ie, interstitial inflammation and 
fibrosis, glomerular sclerosis and mesangial matrix increase, 
vascular intimal proliferation, and tubular atrophy.20 The 
Banff schema and CADI score provide equivalent informa-
tion.3 The change in GPR was significantly worse in the 
high-CADI (median, 7.5) group compared with the low-CADI 
(median, 3) group at 3, 6, and 12 months following conver-
sion.19 In this study, there were 15 patients in the low-CADI 
score group and 16 patients in the high-CADI score groUp.19 
GFR, however, was calculated using the MDRD formula, 19 
unlike the Cockcroft-Gault formula in our study. 
The small number of patients (n = 33) in this study 
makes it less powerful to determine smaller differences 
between groups. However, even given the low power of this 
study, there were statistically significant changes in GFR 
not only within the low-CAN group, but also between 
groups at 1, 3, and 6 months after SRL-R. The changes in 
GFR were not significant between the low-CAN and high-
CAN groups at 12 months, although a trend toward an 
improvement in change in GFR was noted for the low-CAN 
group. Likewise, the retrospective nature of this study is 
suboptimal. Variations in the antibody used for precondi-
tioning and differences in the SRL-R protocol decrease the 
validity of the study design. However, this analysis was 
performed in an unselected group of patients of varying 
ethnicity with prior kidney transplants and with varying 
number of comorbidities. 
Two kinds of protocols exist for switching from CNI-
based to SRL-based immunosuppression. In the protocols 
with an overlap period between CNI and SRL therapy, 
there exists the potential for excessive initial immuno-
suppression and the need for careful therapeutic drug 
monitoring.H The immediate conversion to SRL has the 
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advantage of simplicity and avoids potential overimmu-
nosuppression.21 In the protocols with immediate conver-
sion, the possibility of acute rejection might be increased, if 
the time to achieve target SRL levels is prolonged. 
In a single-center, randomized controlled trial. 40 renal 
transplant recipients between 6 months and 8 years post-
transplantation were randomly assigned to remain on their 
CNI (CsA or TAC) or to switch to SRL?' The principal 
inclusion criteria in this study was suboptimal renal func-
tion, defined as serum creatinine level between 120 and 
400 jLmol/L (1.36-4.52 mg/dL). Two patients never took 
their study drugs, leaving 19 patients in each group. At 
12 months, there was a significant change in GFR following 
conversion to SRL (12.9 mUmin, 95% confidence interval, 
6.1-19.7; P < .001). No patient in either group experienced 
an acute rejection episode. The availability of SRL allows 
substitution for CNI therapy with a non nephrotoxic agent 
and potentially avoids risk of acute rejection.21 No attempt 
was made in this study to quantify the burden of CAN prior 
to switching to SRL.21 
We did not do protocol kidney transplant biopsies in our 
study. Such biopsies could help in documenting the pro-
gression of CAN in the low-CAN and high-CAN score 
groups during the period of follow-up. The Rapamune 
Maintenance Regimen Trial showed that early CsA with-
drawal from a SRL-CsA-steroid (ST) regimeQ. improved 
renal function and histology.22 Protocol mandared biopsies 
were done at engraftment and at 12 and 36 months after 
transplantation. All 6 componenets of the CADI score were 
lower in the patients in the SRL-ST group, who had 
undergone early CsA withdrawal. Inflammation and tubular 
atrophy scores decreased significantly in the SRL-ST 
groups between 12 and 36 months.22 
In summary, the presence of a CAN score ::;4 was 
predictive of improved GFR at 1, 3, and 6 months after 
SRL-R compared with a group of patients with a CAN 
score >4. CAN scoring may be a more reliable predictor of 
allograft function rather than serum creatinine level or 
Cockcroft-Gault GFR measurements. Prospective SRL-R 
trials should be done to confirm the conclusions of this 
study. 
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